Riboway
Cambridge, US · 1 known investors
Riboway Therapeutics develops RNA-targeting technology powered by AI to control protein expression for therapeutic purposes. The company focuses on treating neurodegenerative and metabolic diseases, with programs including an antisense oligonucleotide targeting Spinocerebellar Ataxia Type 2.
Investors · 1
Competitors · 4
by search overlapBioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Relay3 shared keywordsRelay Therapeutics develops small-molecule therapeutics using its Dynamo platform, which combines experimental and computational methods to model protein motion and target proteins considered difficult to drug. Its pipeline focuses on precision oncology and genetic disease.
Crossbow Therapeutics3 shared keywordsCrossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.
Altay Therapeutics3 shared keywordsAltay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer. The company's pipeline includes oral drug candidates designed as first- or best-in-class therapeutics for oncology and inflammatory conditions.
Companies competing with Riboway for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Riboway do?
- Riboway Therapeutics develops RNA-targeting technology powered by AI to control protein expression for therapeutic purposes. The company focuses on treating neurodegenerative and metabolic diseases, with programs including an antisense oligonucleotide targeting Spinocerebellar Ataxia Type 2.
- Who are Riboway's investors?
- Riboway's investors include The Innovation Space.
- Where is Riboway headquartered?
- Riboway is headquartered in Cambridge, US.